Amidase encapsulated O-carboxymethyl chitosan nanoparticles for vaccine delivery

• Amidase encapsulated O-carboxymethyl chitosan nanoparticles were developed.
• These nanoparticles were found to be hemo- and cyto-compatible.
• A sustained release of amidase from O-CMC nanoparticles was observed.
• This sustained release of amidase would prolong its immunogenicity.
• These Ami-O-CMC nanoparticles can be used as a vaccine against S. aureus infections.

This work reports the development of amidase encapsulated O-carboxymethyl chitosan nanoparticles (Ami-O-CMC NPs) of 300 ± 50 nm size by ionic cross-linking method. The prepared Ami-O-CMC NPs had an encapsulation efficiency of 55.39%. Haemolysis assay and cytotoxicity studies proved the hemocompatibility and cytocompatibility of the prepared NPs. The sustained release of Ami from the NPs is expected to prolong its immunogenicity and in turn lead to development of better protective immunity against Staphylococcus aureus infections.